MX2009005449A - Compuesto heteromonociclico y uso del mismo. - Google Patents

Compuesto heteromonociclico y uso del mismo.

Info

Publication number
MX2009005449A
MX2009005449A MX2009005449A MX2009005449A MX2009005449A MX 2009005449 A MX2009005449 A MX 2009005449A MX 2009005449 A MX2009005449 A MX 2009005449A MX 2009005449 A MX2009005449 A MX 2009005449A MX 2009005449 A MX2009005449 A MX 2009005449A
Authority
MX
Mexico
Prior art keywords
formula
compound
group
group represented
alkylamino
Prior art date
Application number
MX2009005449A
Other languages
English (en)
Inventor
Takanobu Kuroita
Hiroki Sakamoto
Hideyuki Igawa
Minoru Sasaki
Kouhei Asano
Tsuyoshi Maekawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2009005449A publication Critical patent/MX2009005449A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de la presente invención representado por la fórmula (I): (ver fórmula (I)) en donde R1 es un grupo oxo, =N-R o similar; un grupo representado por la fórmula: (ver fórmula) es un grupo representado por la formula: (ver fórmulas) R2 es un grupo representado por la fórmula: (ver fórmula) R3 y R4 son cada uno H, o C1-C6 alquilo, C3-C6 cicloalquilo, C1-C6 alcoxi, C1-C6 alquilamino, di(C1-C6)alquilamino o C1-C6 alquiltio, cada uno de los cuales es opcionalmente substituido; y R5 es H, o un grupo C1-C6 alquilo, C2-C6 alquenilo, cíclico, cada uno de los cuales es opcionalmente substituido, -CO-R8 o -O-R8', o una sal del mismo. El compuesto de la presente invención es útil como un fármaco para la profilaxis o tratamiento de enfermedades circulatorias, enfermedades metabólicas y/o enfermedades del sistema nervioso central.
MX2009005449A 2006-11-24 2007-11-21 Compuesto heteromonociclico y uso del mismo. MX2009005449A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006317839 2006-11-24
JP2007232106 2007-09-06
PCT/JP2007/073004 WO2008062905A2 (en) 2006-11-24 2007-11-21 Heteromonocyclic compound and use thereof

Publications (1)

Publication Number Publication Date
MX2009005449A true MX2009005449A (es) 2009-06-02

Family

ID=39205144

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005449A MX2009005449A (es) 2006-11-24 2007-11-21 Compuesto heteromonociclico y uso del mismo.

Country Status (21)

Country Link
US (2) US20080207654A1 (es)
EP (2) EP2074117A2 (es)
JP (1) JP2010510962A (es)
KR (1) KR20090085117A (es)
AR (1) AR063912A1 (es)
AU (1) AU2007322608A1 (es)
BR (1) BRPI0719060A2 (es)
CA (1) CA2670404A1 (es)
CL (1) CL2007003352A1 (es)
CO (1) CO6231035A2 (es)
CR (1) CR10847A (es)
EA (1) EA200970510A1 (es)
EC (1) ECSP099461A (es)
IL (1) IL198819A0 (es)
MA (1) MA30985B1 (es)
MX (1) MX2009005449A (es)
NO (1) NO20092415L (es)
PE (1) PE20081228A1 (es)
TN (1) TN2009000199A1 (es)
TW (1) TW200829581A (es)
WO (1) WO2008062905A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7103906B1 (en) 2000-09-29 2006-09-05 International Business Machines Corporation User controlled multi-device media-on-demand system
DK1327209T3 (da) 2000-10-11 2008-12-08 United Video Properties Inc Systemer og fremgangsmåder til tilvejebringelse af lagring af data på servere i et on-demand-medieleveringssystem
US8086575B2 (en) 2004-09-23 2011-12-27 Rovi Solutions Corporation Methods and apparatus for integrating disparate media formats in a networked media system
US8607287B2 (en) 2005-12-29 2013-12-10 United Video Properties, Inc. Interactive media guidance system having multiple devices
US9681105B2 (en) 2005-12-29 2017-06-13 Rovi Guides, Inc. Interactive media guidance system having multiple devices
US7803940B2 (en) * 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
BRPI0719060A2 (pt) * 2006-11-24 2014-02-04 Takeda Pharmaceutical Composto, prodroga, agente farmacêutico, métodos para inibir um receptor de angiotensina ii e/ou ativar um receptor ativado com proliferador de peroxisoma, e para prevenir ou tratar doenças ou condições, e, uso de um composto
US20090019492A1 (en) 2007-07-11 2009-01-15 United Video Properties, Inc. Systems and methods for mirroring and transcoding media content
PL2384327T3 (pl) 2009-01-30 2013-12-31 Takeda Pharmaceuticals Co Związki ze skondensowanym pierścieniem i ich zastosowanie
EP2399917A1 (en) 2009-02-23 2011-12-28 Kowa Company, Ltd. Novel compounds comprising a 3-(5-alkoxypyrimidin-2-yl) pyrimidin-4(3h)-one structure and drugs that comprise same
JPWO2010119700A1 (ja) * 2009-04-17 2012-10-22 興和株式会社 新規な３−ヘテロアリールピリミジン−４−（３ｈ）−オン構造を有する化合物及びこれを含有する医薬
WO2010137336A1 (ja) 2009-05-29 2010-12-02 興和株式会社 新規なα－フェノキシベンゼン酢酸誘導体及びこれを含有する医薬
EP2471782A4 (en) 2009-08-27 2013-03-20 Kowa Co NEW SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
US9014546B2 (en) 2009-09-23 2015-04-21 Rovi Guides, Inc. Systems and methods for automatically detecting users within detection regions of media devices
WO2011040004A1 (ja) 2009-09-29 2011-04-07 興和株式会社 新規なフェニルピリジン誘導体及びこれを含有する医薬
US20120225896A1 (en) * 2009-12-22 2012-09-06 Kowa Company, Ltd. Novel 2-pyridone derivative and pharmaceutical product containing same
WO2011105099A1 (ja) * 2010-02-25 2011-09-01 興和株式会社 新規な４－アルコキシピリミジン構造を有する化合物及びこれを含有する医薬
CA2835596A1 (en) * 2010-05-11 2011-11-17 8337187 Canada Inc. Benzo- or pyrido-imidazole derivative
WO2012011592A1 (ja) * 2010-07-23 2012-01-26 武田薬品工業株式会社 複素環化合物およびその用途
AU2011313150A1 (en) 2010-10-07 2013-04-18 Takeda Pharmaceutical Company Limited 1,4-oxazepane derivatives
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
PL2648516T3 (pl) 2010-12-06 2019-04-30 Aclaris Therapeutics Inc Podstawione związki pirydynono-pirydynylowe
US8507499B2 (en) 2010-12-06 2013-08-13 Confluence Life Sciences, Inc. Substituted indole/indazole-pyrimidinyl compounds
US8563558B2 (en) 2010-12-06 2013-10-22 Confluence Life Sciences, Inc. Substituted pyridine urea compounds
EP2687523B1 (en) 2011-03-14 2016-01-06 Kowa Company Ltd. Novel phenylpyridine derivative and drug containing same
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013086208A1 (en) 2011-12-06 2013-06-13 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
AU2012356374B2 (en) * 2011-12-21 2017-06-22 Ono Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CA2917344C (en) 2013-06-07 2021-09-07 Confluence Life Sciences, Inc. Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
CN105722830B (zh) 2013-06-20 2019-06-04 拜耳作物科学股份公司 作为杀螨剂和杀昆虫剂的芳基硫醚衍生物和芳基亚砜衍生物
BR112015031291A2 (pt) 2013-06-20 2017-07-25 Bayer Cropscience Ag derivados de sulfureto de arila e derivados de arilalquil sulfóxido como acaricidas e inseticidas
US9674563B2 (en) 2013-11-04 2017-06-06 Rovi Guides, Inc. Systems and methods for recommending content
JP6454348B2 (ja) 2013-12-19 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 窒素複素環誘導体およびその医薬品への応用
US10004740B2 (en) 2014-04-01 2018-06-26 Merck Sharp & Dohme Corp. Prodrugs of HIV reverse transcriptase inhibitors
ES2814098T3 (es) 2014-12-10 2021-03-26 Ono Pharmaceutical Co Derivado de dihidroindolizinona
MX2019000512A (es) 2016-07-12 2019-05-02 Bayer Cropscience Ag Compuestos biciclicos como plaguicidas.
KR101984121B1 (ko) * 2017-08-21 2019-05-30 보령제약 주식회사 피리미디논 유도체 화합물 및 이의 용도
JP2023519890A (ja) 2020-03-27 2023-05-15 アクラリス セラピューティクス，インコーポレイテッド 免疫状態の処置のためのｍｋ２経路阻害剤の経口組成物
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411980A (en) * 1989-07-28 1995-05-02 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
ATE113281T1 (de) * 1989-08-02 1994-11-15 Takeda Chemical Industries Ltd Pyrazol-derivate, verfahren zu deren herstellung und anwendung.
JPH03218371A (ja) 1989-08-02 1991-09-25 Takeda Chem Ind Ltd ピラゾール誘導体
JP3032844B2 (ja) 1990-02-15 2000-04-17 武田薬品工業株式会社 ピリミジンジオン誘導体
US5162326A (en) * 1990-02-15 1992-11-10 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
CA2037630C (en) 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
JP3114073B2 (ja) 1990-03-07 2000-12-04 武田薬品工業株式会社 アンジオテンシンｉｉ拮抗薬−含窒素異項環化合物
US5166206A (en) * 1990-03-30 1992-11-24 Merck & Co., Inc. Substituted pyrimidines, pyrimidinones and pyridopyrimidines
US5472967A (en) * 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
IT1250749B (it) * 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
JPH06239859A (ja) 1992-09-14 1994-08-30 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する環状化合物およびその用途
ATE264323T1 (de) 1992-09-14 2004-04-15 Takeda Chemical Industries Ltd Heterocyclische verbindungen und ihre verwendung als angiotensin ii antagonisten
JP3412887B2 (ja) 1992-12-22 2003-06-03 武田薬品工業株式会社 アンギオテンシンｉｉ拮抗作用を有する複素環化合物およびその用途
DE69330593T2 (de) 1992-12-22 2002-06-27 Takeda Chemical Industries Ltd Heterocyclische Verbindungen mit Angiotensin-II-antagonistischer Wirkung und ihre Anwendung
US20010020100A1 (en) * 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
WO1999022735A1 (en) 1997-10-30 1999-05-14 Merck & Co., Inc. Somatostatin agonists
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
AU7556800A (en) 1999-10-07 2001-05-10 Tadeka Chemical Industries, Ltd. Amine derivatives
MY141468A (en) 1999-11-10 2010-04-30 Takeda Pharmaceutical 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US6930185B2 (en) 2000-04-28 2005-08-16 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
WO2001087834A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
KR100866820B1 (ko) 2000-07-13 2008-11-04 다케다 야쿠힌 고교 가부시키가이샤 지질 풍부 플라크 퇴축제
US20050245571A1 (en) 2001-10-19 2005-11-03 Hidenori Abe Amine derivative
AU2003202488A1 (en) 2002-01-11 2003-07-30 Takeda Pharmaceutical Company Limited Coumarin derivatives, process for their production and use thereof
EP1564213A4 (en) 2002-11-22 2009-05-27 Takeda Pharmaceutical IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF
US7803940B2 (en) * 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
BRPI0719060A2 (pt) * 2006-11-24 2014-02-04 Takeda Pharmaceutical Composto, prodroga, agente farmacêutico, métodos para inibir um receptor de angiotensina ii e/ou ativar um receptor ativado com proliferador de peroxisoma, e para prevenir ou tratar doenças ou condições, e, uso de um composto

Also Published As

Publication number Publication date
BRPI0719060A2 (pt) 2014-02-04
JP2010510962A (ja) 2010-04-08
EA200970510A1 (ru) 2009-12-30
CR10847A (es) 2009-07-13
AR063912A1 (es) 2009-02-25
AU2007322608A2 (en) 2009-07-16
US20080207654A1 (en) 2008-08-28
WO2008062905A3 (en) 2008-12-04
TW200829581A (en) 2008-07-16
CO6231035A2 (es) 2010-12-20
CA2670404A1 (en) 2008-05-29
KR20090085117A (ko) 2009-08-06
PE20081228A1 (es) 2008-10-29
IL198819A0 (en) 2010-02-17
EP2256115A1 (en) 2010-12-01
AU2007322608A1 (en) 2008-05-29
ECSP099461A (es) 2009-11-30
NO20092415L (no) 2009-08-17
TN2009000199A1 (en) 2010-10-18
WO2008062905A2 (en) 2008-05-29
US20100056526A1 (en) 2010-03-04
CL2007003352A1 (es) 2008-07-04
MA30985B1 (fr) 2009-12-01
EP2074117A2 (en) 2009-07-01

Similar Documents

Publication Publication Date Title
MX2009005449A (es) Compuesto heteromonociclico y uso del mismo.
RS20060699A (en) Isoxazolines for controlling inverterbrate pests
MY168201A (en) Agricultural And Horticultural Fungicidal Composition
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
MX344669B (es) Agente antiplaquetas novedoso.
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
CO5590957A2 (es) Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas
MX2010002820A (es) Analogos de tiazolidindiona para tratamiento de hipertension.
TW200732333A (en) An oxime derivative and preparations thereof
NO20080391L (no) Pyrazolbaserte LXR modulatorer
MX2008012404A (es) Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g.
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
NZ630259A (en) Heterobicyclic compounds as beta-lactamase inhibitors
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
TW200621694A (en) Substituted n-sulfonylaminobenzyl-2-phenoxyacetamide compounds
ZA200810739B (en) Pesticide containing novel pyridyl-methanamine derivative or its salt
NZ581438A (en) Kallikrein 7 modulators
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
PE20070814A1 (es) Compuestos derivados de 2-carboxitiofeno como inhibidores de la polimerasa del virus de la hepatitis c (hcv)
MX2009008781A (es) Derivados de ciclohexano espirociclicos.
MX335989B (es) Compuesto adecuado para el tratamiento de sinucleopatias.
MX2009008772A (es) Derivado piridil-triazolopirimidina o su sal, pesticida que lo contiene y proceso para su produccion.
BRPI0721113A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal